Nothing Special   »   [go: up one dir, main page]

DK3278803T3 - Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor - Google Patents

Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor Download PDF

Info

Publication number
DK3278803T3
DK3278803T3 DK16771410.4T DK16771410T DK3278803T3 DK 3278803 T3 DK3278803 T3 DK 3278803T3 DK 16771410 T DK16771410 T DK 16771410T DK 3278803 T3 DK3278803 T3 DK 3278803T3
Authority
DK
Denmark
Prior art keywords
dosage form
pharmaceutical dosage
solid pharmaceutical
parp inhibitor
parp
Prior art date
Application number
DK16771410.4T
Other languages
English (en)
Inventor
Suixiong Cai
Yushen Guo
Original Assignee
Impact Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Therapeutics Shanghai Inc filed Critical Impact Therapeutics Shanghai Inc
Application granted granted Critical
Publication of DK3278803T3 publication Critical patent/DK3278803T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16771410.4T 2015-04-03 2016-04-01 Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor DK3278803T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510157453 2015-04-03
PCT/CN2016/078262 WO2016155655A1 (zh) 2015-04-03 2016-04-01 Parp抑制剂固体药物剂型及其应用

Publications (1)

Publication Number Publication Date
DK3278803T3 true DK3278803T3 (da) 2022-08-29

Family

ID=57003934

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16771410.4T DK3278803T3 (da) 2015-04-03 2016-04-01 Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor

Country Status (10)

Country Link
US (2) US11179392B2 (da)
EP (1) EP3278803B1 (da)
JP (1) JP6878398B2 (da)
KR (1) KR102013440B1 (da)
CN (1) CN107405349B (da)
AU (1) AU2016239141B2 (da)
CA (1) CA2981627C (da)
DK (1) DK3278803T3 (da)
ES (1) ES2922637T3 (da)
WO (1) WO2016155655A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017167251A1 (zh) * 2016-04-01 2017-10-05 上海瑛派药业有限公司 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺
CN112004529B (zh) 2018-04-06 2023-08-08 比利时胶囊公司 包含聚[(甲基丙烯酸甲酯)-共-(甲基丙烯酸)]的低纵横比颗粒的喷雾干燥方法
WO2019207498A1 (en) * 2018-04-25 2019-10-31 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-fluoro-2-{4-[(methylamino)methyl] phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd] indol-6-one ((1s,4r)-7,7dimethyl-2-oxobicyclo [2.2.1] hept-1-yl) methanesulfonic acid salt (rucaparib camsylate) and the prerparation thereof
CA3109386A1 (en) 2018-08-17 2020-03-19 Ptc Therapeutics, Inc. Use of 5-fluoro-2-(6-fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine in the treatment of pancreatic cancer
US20230263801A1 (en) * 2020-07-24 2023-08-24 Impact Therapeutics (Shanghai), Inc Combination therapy of parp inhibitors
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
WO2022099442A1 (zh) * 2020-11-10 2022-05-19 上海瑛派药业有限公司 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
MX2023011331A (es) * 2021-03-26 2023-10-03 Impact Therapeutics Shanghai Inc Capsula oral de inhibidor de parp y metodo de preparacion de la misma.
WO2023138667A1 (zh) * 2022-01-21 2023-07-27 上海瑛派药业有限公司 Senaparib和替莫唑胺的复方制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1885338A1 (en) * 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
JP2007131577A (ja) * 2005-11-10 2007-05-31 Mochida Pharmaceut Co Ltd 3−クロメニル−ピリドキナゾリン−1−オン誘導体
AU2008218248A1 (en) 2007-02-23 2008-08-28 Avera Pharmaceuticals, Inc. Pharmaceutical formulation
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
CA3097370A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
CN103443085B (zh) * 2011-03-14 2016-03-23 南京英派药业有限公司 喹唑啉二酮及其应用
CN102731416A (zh) * 2011-04-01 2012-10-17 南京英派药业有限公司 1-(芳基甲基)-喹唑啉-2,4-二酮作为parp抑制剂及其应用
TWI527800B (zh) * 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚(二磷酸腺苷酸-核醣)聚合酶(parp)之抑制劑之1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮及其應用
US20150011525A1 (en) * 2011-09-13 2015-01-08 Isp Investments Inc. Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
US9102631B2 (en) 2011-11-01 2015-08-11 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof

Also Published As

Publication number Publication date
CA2981627A1 (en) 2016-10-06
EP3278803A4 (en) 2018-11-07
EP3278803B1 (en) 2022-06-22
US11179392B2 (en) 2021-11-23
EP3278803A1 (en) 2018-02-07
ES2922637T3 (es) 2022-09-19
AU2016239141B2 (en) 2019-04-18
JP6878398B2 (ja) 2021-05-26
CA2981627C (en) 2024-02-20
JP2018510221A (ja) 2018-04-12
CN107405349A (zh) 2017-11-28
WO2016155655A1 (zh) 2016-10-06
AU2016239141A1 (en) 2017-11-09
US20180071290A1 (en) 2018-03-15
CN107405349B (zh) 2021-03-02
KR20170132881A (ko) 2017-12-04
KR102013440B1 (ko) 2019-08-22
US20220031702A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
NL301217I2 (nl) tirzepatide en farmaceutisch aanvaardbare zouten daarvan
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3317286T3 (da) Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3259253T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3212230T3 (da) Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer
DK3359241T3 (da) Formuleringer af pthrp-analoger, transdermale plastre deraf og anvendelser deraf
MA46193A (fr) Inhibiteurs hétéroaryles de pad4
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3313833T3 (da) Forbindelser og anvendelse deraf som inhibitorer af n-myristoyl-transferase
DK3594343T3 (da) Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK2958573T3 (da) Farmaceutiske formuleringer af nitrit og anvendelser deraf
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
DK3355890T3 (da) Humane plasmakallikreininhibitorer
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3310331T3 (da) Injicerbare farmaceutiske formuleringer af lefamulin
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde